Cargando…

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system’s ability to recognize and des...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oncale, Melody B, Maymani, Hossein, Nastoupil, Loretta J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467338/ https://www.ncbi.nlm.nih.gov/pubmed/31360081 http://dx.doi.org/10.2147/BLCTT.S110665

Ejemplares similares

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale
por: Gordon, Max J., et al.
Publicado: (2023)

Harnessing the immune system in the treatment of cutaneous T cell lymphomas
por: Fay, Christopher J., et al.
Publicado: (2023)

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma
por: Visweshwar, Nathan, et al.
Publicado: (2023)

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)

Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor
por: Bouzari, Behnaz, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma
por: Maggioncalda, Alison, et al.
Publicado: (2011)

Immunophenotype evaluation of Non-Hodgkin’s lymphomas
por: Sheikhpour, Robab, et al.
Publicado: (2017)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2022)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
por: Renner, Christoph, et al.
Publicado: (2018)

The role of trogocytosis in immune surveillance of Hodgkin lymphoma
por: Zeng, Qun, et al.
Publicado: (2020)

Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma
por: Bertuzzi, Clara, et al.
Publicado: (2021)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Proton therapy in the management of non-Hodgkin lymphoma
por: Sachsman, Suzanne, et al.
Publicado: (2015)

Advanced stage Hodgkin Lymphoma: patient management
por: Gini, Guido, et al.
Publicado: (2020)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
por: Zhao, Shu, et al.
Publicado: (2018)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Exploring Risk Factors for Follicular Lymphoma
por: Ambinder, Alexander J., et al.
Publicado: (2012)

Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma
por: Schuetz, Johanna M., et al.
Publicado: (2012)

Assessing Prognostic Factors in Hodgkin's Lymphoma: Multistate Illness-Death Model
por: Javanmardi, Fatemeh, et al.
Publicado: (2018)

Immune Response to Combination Therapy for Non-Hodgkin Lymphomas
por: Weiss, Robert F., et al.
Publicado: (2013)

Several immune escape patterns in non-Hodgkin's lymphomas
por: Laurent, Camille, et al.
Publicado: (2015)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature
por: Ko, Heidi, et al.
Publicado: (2016)

Harnessing the immune system in glioblastoma
por: Brown, Nicholas F., et al.
Publicado: (2018)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma
por: Luminari, Stefano, et al.
Publicado: (2011)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Management of Non-Hodgkin's Lymphoma in Maxillofacial Region with Chemotherapy
por: Moin, Ayesha, et al.
Publicado: (2017)

Contemporary Management of Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p3an398htv77e9829boc7lnajf